Edgewise Therapeutics Inc (EWTX)

Currency in USD
41.37
-0.67(-1.59%)
Closed·
41.370.00(0.00%)
·
EWTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
40.3242.37
52 wk Range
19.7648.78
Key Statistics
Prev. Close
41.37
Open
42.03
Day's Range
40.32-42.37
52 wk Range
19.76-48.78
Volume
866.83K
Average Volume (3m)
1.54M
1-Year Change
85.1835%
Book Value / Share
15.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EWTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
55.42
Upside
+33.95%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Edgewise Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

12 Buy
1 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 55.42
(+33.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Sell85.00+105.46%66.00MaintainNov 05, 2026
William Blair
Buy---New CoverageOct 16, 2026
H.C. Wainwright
Buy57.00+37.78%-MaintainOct 14, 2026
H.C. Wainwright
Buy57.00+37.78%45.00MaintainSep 21, 2026
JPMorgan
Buy60.00+45.03%53.00MaintainAug 20, 2026

Edgewise Therapeutics Inc SWOT Analysis


Novel Therapies
Edgewise Therapeutics develops innovative treatments for rare muscle disorders, with lead candidate EDG-7500 in clinical trials for hypertrophic cardiomyopathy
Clinical Milestones
Explore the company's catalyst-rich 2025, featuring crucial data readouts for EDG-7500 and sevasemten in muscular dystrophy programs
Market Potential
Delve into Edgewise's positioning in the lucrative rare disease market, addressing significant unmet needs in HCM and muscular dystrophy
Analyst Outlook
Learn about the bullish sentiment surrounding EWTX, with price targets ranging from $30 to $56, reflecting substantial upside potential
Read full SWOT analysis

Earnings

Latest Release
Nov 05, 2026
EPS / Forecast
9.65 / -0.53
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EWTX Income Statement

Compare EWTX to Peers and Sector

Metrics to compare
EWTX
Peers
Sector
Relationship
P/E Ratio
4.5x−1.9x−0.2x
PEG Ratio
0.01−1.320.00
Price/Book
2.8x0.6x2.6x
Price / LTM Sales
-1.7x2.7x
Upside (Analyst Target)
34.0%107.7%69.6%
Fair Value Upside
Unlock12.9%11.7%Unlock

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
31.91M29.15%1.39B
Other Institutional Investors
106.49M70.85%4.65B
Public Companies & Retail Investors
0.000.00%0.00
Total
138.4M100.00%6.05B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
OrbiMed Advisors LLC14.17%15,518,492677,848
OrbiMed Private Investments VI, LP13.53%14,809,075646,860

People Also Watch

34.39
XNCR
-0.32%
13.760
ERAS
-0.94%
9.01
CGEM
-2.91%

FAQ

What Is the Edgewise Therapeutics (EWTX) Stock Price Today?

The Edgewise Therapeutics stock price today is 41.37 USD.

What Stock Exchange Does Edgewise Therapeutics Trade On?

Edgewise Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Edgewise Therapeutics?

The stock symbol for Edgewise Therapeutics is "EWTX."

What Is the Edgewise Therapeutics Market Cap?

As of today, Edgewise Therapeutics market cap is 4.53B USD.

What Is Edgewise Therapeutics's Earnings Per Share (TTM)?

The Edgewise Therapeutics EPS (TTM) is 9.40.

When Is the Next Edgewise Therapeutics Earnings Date?

Edgewise Therapeutics will release its next earnings report on Feb 25, 2027.

From a Technical Analysis Perspective, Is EWTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Edgewise Therapeutics Stock Split?

Edgewise Therapeutics has split 0 times.

How Many Employees Does Edgewise Therapeutics Have?

Edgewise Therapeutics has 133 employees.

What is the current trading status of Edgewise Therapeutics (EWTX)?

As of Nov 19, 2026, Edgewise Therapeutics (EWTX) is trading at a price of 41.37 USD, with a previous close of 41.37 USD. The stock has fluctuated within a day range of 40.32 USD to 42.37 USD, while its 52-week range spans from 19.76 USD to 48.78 USD.

What Is Edgewise Therapeutics (EWTX) Price Target According to Analysts?

The average 12-month price target for Edgewise Therapeutics is 55.42 USD, with a high estimate of 85 USD and a low estimate of 36 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +33.95% Upside potential.

What Is the EWTX Premarket Price?

EWTX's last pre-market stock price is 42.05 USD. The pre-market share volume is 1,210.00, and the stock has decreased by 0.01, or 0.02%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.